Applications to ECA 2018 are now closed.
Le Hoa Mai
Akpéli Nordor is a pharmacist-scientist leveraging genomic data sciences to explore cancer biology. His work focuses on comparative studies of the regulation of placental implantation and tumour development, with the hope of developing innovative cancer biomarkers and immunotherapies. Dr. Nordor is a research fellow at Institut Curie (Paris) and Massachusetts General Hospital (Boston). He completed a dual PharmD-PhD curriculum at Université Paris Descartes / Paris Sorbonne Cité and advanced research training at Harvard Medical School.
Susanne Neumann has a MSc in molecular biology with a specialization in neuroscience from the University of Jena. Under the leadership of Prof. Lou Brundin at Karolinska Institutet in Sweden, she is investigating neural repair/stem cell biology for prospective therapies treating diseases of the nervous system like multiple sclerosis. She is very interested in innovation and particularly fascinated by the development of new biomaterials facilitating drug delivery and healing. She hopes to contribute to improvement of patient’s life quality with her research.
Dr Krista Stockenhuber obtained her medical degree from the Medical University of Vienna in 2011. She completed a Wellcome Trust funded PhD at the University of Oxford in 2015. Her work was supervised by Professors Powrie and Ogg and focused on novel mechanisms of immune regulation at barrier surfaces, in particular the skin and intestinal tract. She is currently continuing her medical training in Oxford and aims to combine her passion for translational and clinical medicine with the focus on gastrointestinal immune regulation.
Pr. Philippe Blancou obtained his PhD in Virology at Pasteur Institute, Paris, France. After several years of research in the field of HIV vaccines, he shifted his research focus to Immuno-Mediated Inflammatory Diseases (IMIDs) and became increasingly interested in the interaction between the neural and the immune systems. He started a collaboration with Galvani (a R&D company founded by Alphabet Inc. and pharmaceutical company GlaxoSmithKline) on the potential use of bioelectronics as therapy to treat IMIDs. He is currently a group leader at CNRS-IPMC in Sophia Antipolis, France.
Dr Hehle is an antibody-biotechnologist with over 10 years experience in a multidisciplinary context of therapeutic antibody discovery, molecular biology (in human and plants) and infectious diseases with a good understanding of the pharmaceutical and biotechnology industry. Dr Hehle obtained a PhD from St George’s University in London, investigating the enzymatic degradation of antibodies expressed in tobacco plants. Dr Hehle is currently leading the pre-clinical development of therapeutic antibodies against a chronic viral disease at the Institut Pasteur in Paris.
One of Dr Thomas Simon’s goals during the past 10 years has been investigating the mechanisms involved in the modulation of the immune system. During his PhD, Dr Simon worked on mechanisms that improved the functions of dendritic cells for the activation of the immune system. He then studied the role of these cells and stromal laminins in the induction of tolerance. His research program is now focused on the use of bioelectronics as therapy to treat autoimmune diseases.
Dr. Victor Greiff is an Associate Professor for Computational and Systems Immunology at the University of Oslo, Norway.
His research focuses on developing novel computational and experimental strategies for designing next-generation therapeutics, diagnostics and vaccines against infectious and autoimmune diseases and cancer by combining high-throughput antibody and T-cell receptor sequencing with artificial intelligence. He is actively involved in many global collaborations with industry, clinicians, and academia.
After 5 years of pharmacy studies at the University of Nantes, Valentin Quiniou passed the national competitive examination for Pharmacy specialty and begun his residency in Immunology and Biotherapies at AP-HP. At the same time, Valentin obtained a Master degree in biomedical engineering and began his PhD/MBA with Pr. David Klatzmann to decipher the T cell repertoire in human. Valentine is currently a university hospital assistant and wishes to continue his career as a scientific entrepreneur in the private sector.
Sandy Azzi-Hatem obtained her PhD in Biochemistry and Oncology in 2011. She then joined Institut Cochin (Paris) and next Hopital Paul Brousse as a research fellow to study the tumor/vascular-niche cross-talk in Glioblastoma and Kidney cancer respectively. She also received training in patent and innovation management. She currently holds a scientific manager and business developer position at Institut Curie, aiming to foster the transfer from basic research to clinical development mainly in pediatric oncology.
Marcelo Hill (42) is MD (Universidad de la Republica, Uruguay) and PhD in immunology (Université de Nantes, France). He is the Director of the FOCIS Centre of Excellence “Centre for Translational Immunology” at Institut Pasteur Montevideo. Dr Hill is Associate Professor of immunology at Universidad de la Republica. He is founder and CSO of ARDAN Immuno Pharma.
Leila Amini is a PhD candidate developing and investigating advanced strategies of antiviral adoptive T cell therapy at the Charité in Berlin. She focuses on characterization of T cell products and refinement of application-oriented and GMP-conform protocols to accelerate clinical translation. Previously, she graduated at Master of Science in Molecular Medicine from the Charité in Berlin and as Bachelor of Science in Molecular Biomedicine from the University of Bonn.
Le Hoa Mai
Dr Le Hoa Mai, MD, PhD is currently a researcher at CRTI, INSERM 1064 – a FOCIS Center of Excellence – CHU Nantes, Universite de Nantes, France. He began his career as a clinician and university lecturer in Vietnam, underwent nephrology training in Japan and in France, received a PhD in biology from Universite de Nantes, and thereafter dedicated all his time to biomedical research looking for novel therapeutic targets in transplantation and autoimmune and inflammatory diseases.
Dr Johan Gising, pharmacist and medicinal chemist, defended his thesis in 2012 in the area of infectious diseases at Uppsala University. He now oversees chemistry resources to programmes and hold project management roles in ENABLE (IMI/ND4BB) for development of gram-negative antibiotics from hits to phase 1 clinical trials. He is also engaged in drug discovery and development in angiotensin related research projects at the department of Medicinal Chemistry, Uppsala University, Sweden.
James Arnold obtained his DPhil at the University of Oxford in 2006 and then went onto the University of Cambridge where he became interested in the field of Tumour Immunology. In 2010 James became a Fellow of the Cancer Research Institute until he acquired a Lectureship at King’s College London in 2012. James’ lab now explore therapeutic targets in the tumour microenvironment, with the aim to improve the immune response against cancer.
Hussein Al-Mossawi completed his medical degree at Oxford in 2006 followed by specialist training in Rheumatology. He completed his PhD at Oxford, supervised by Professors Bowness and Powrie and funded by a Wellcome trust fellowship, focusing on the role of GM-CSF in spondyloarthritis. This work has informed an investigator led clinical trial with industry collaboration. He is currently an Academic Clinical Lecturer in Rheumatology at Oxford and the recipient of the Oxford-UCB prize fellowship.
Federico Colombo is currently working as a postdoctoral researcher at the Department of Life Sciences, University of Trieste, Italy. His research focuses on the development of targeted delivery systems as innovative and improved approaches for the treatment and the diagnosis of chronic joint diseases, such as Rheumatoid Arthritis (RA) and Osteoarthritis (OA). He graduated in Functional Genomics (MSc) in 2012 and, in early 2018, he obtained the PhD in Nanotechnology from the University of Trieste, investigating the efficacy of targeted drug-loaded biodegradable polymeric nanoparticles in pre-clinical models of RA.
Dr. Enrico Catalano BSc, Biotechnology Scientist, Nanomedicine researcher, Biologist, Ph.D. He graduated in Medical Biotechnology and Molecular Medicine. He has obtained his PhD in Biotechnologies for human health at University of Piemonte Orientale (Italy) with a project for the application of nanomedicine for anticancer therapies. His research topic focuses on the development of new solutions of targeted immunotherapies and nanoimmunotherapy to fight metastatic cancer. In 2018 he was selected as one of the top 500 worldwide young scientists to participate in the 68th Lindau Nobel Meeting. He was awarded the ImmunoTools special Award 2014 for “The role of the immune microenvironment in tumor progression” and in 2016 for NanoInnovation Got Talent. He is now Marie-Curie Scientia Fellows postdoc at University of Oslo with a project entitled: “New therapeutic approaches for personalized breast cancer nanomedicine”. He has authored 30 articles in International scientific journals, has obtained 38 Grants and awards and 2 international patents.
Dr Anton Gisterå received his medical degree in 2010 from Uppsala University and his PhD in 2016 from Karolinska Institute. His present work combines clinical work at Karolinska University hospital with translational research at Karolinska Institute. His research focus is on the role of adaptive immunity in atherosclerosis. The aim is to develop a vaccine against atherosclerosis that could prevent clinical manifestations such as myocardial infarction and ischemic stroke.
Dr Amedee RENAND is specialized in human immunology. He obtained his PhD degree in 2011 under the supervision of Pr. Olivier HERMINE (Necker Hospital, Paris, France). During his first post doctoral training (2012-2015) in Seattle (USA), at the Benaroya Research Institute, in the Kwok lab, he characterized the allergen-specific CD4 T cell response linked to allergic disorders in patients. Since 2015, he has been developing translational research programs to understand immune alterations linked to clinical status during autoimmune liver diseases (Inserm UMR1064, Nantes, France).
Dr Cribbs obtained his PhD in molecular immunology at the Kennedy Institute of Rheumatology, Oxford. He then spent time as a postdoctoral scientist in Professor Sir Marc Feldmann’s and Professor Udo Oppermann’s laboratories in Botnar Research Centre, before undertaking an MRC fellowship in computational biology. Dr Cribbs is now group leader in systems biology, University of Oxford, focussing on identifying therapeutic intervention points in epigenetic pathways that control immune cell function in cancer.
Dr Max Winerdal earned his MD in 2008 at the Karolinska Institute, Sweden, followed by a research internship at Karolinska University Hospital in parallel to his postgraduate studies. In February 2014, Dr Winerdal earned his PhD from the Department of Women´s and Children´s Health, the Karolinska Institute, which focused on neuroinflammation in neonatal brain injury. Since then he has developed novel statistical methods for basic science and drug discovery in parallel to a residency in psychiatry.
Dr Lynn Williams studied Biochemistry at Imperial College London, and then obtained her PhD in Immunology at the Kennedy Institute of Rheumatology, Oxford. She spent two years working at Novartis before returning to the Kennedy Institute to lead multiple industrial collaborations. Dr Williams has had the privilege of observing the development of translational medicine at the Kennedy Institute and the transformation infliximab and other anti-TNF based biologicals have had on the lives of rheumatoid arthritis patients.
Andrea Tucci (MSc) trained as a Medical Biotechnologist at San Raffaele University (Italy) and Yale University (USA). During his studies at the Yale School of Medicine, he investigated how tissue-specific molecular signals shape macrophage polarization. He is now working towards a PhD in Molecular and Cellular Medicine at the University of Oxford. His current research focus is the identification and characterization of novel molecular pathways involved in Th17-driven inflammatory diseases like Crohn’s disease and psoriasis.
Deepak Balaji TG holds an MEng from BITS Pilani, India, MS in Molecular Engineering from NUS Singapore-MIT Boston USA and a PhD in Biomedical Sciences from KU Leuven, Belgium. Deepak has worked at EMBL Grenoble as a Marie-Curie CoFund postdoc fellow. Deepak has worked as a scientific consultant in an Indian start-up company, and been selected as a top 6 finalist for a business idea in the Stanford University-Ignite 2015 cohort. Currently, Deepak is working as a sandwich postdoc fellow at Oslo University hospital in partnership with NCMM-EMBL and UiO.
Dr Michael Schmueck-Henneresse is an immunologist at the Berlin Brandenburg Center for Regenerative Therapies at Charité University Berlin, Germany. He did a postdoctoral posting in the laboratory of Professor Rooney at the Center for Cell and Gene Therapy in Houston, USA. He is currently a junior group leader, primarily designing research approaches that build the groundwork for GMP-compatible protocols comprising the generation of virus-specific immunotherapeutic cellular products to investigate their clinical potential in transplantation and immune-related diseases.
Michael Saitakis is currently working as a project manager for industrial collaborations in Institut Curie’s Center of Cancer Immunotherapy, Paris. He has a strong background in whole cell assay development and human T cell biology. He obtained his PhD in from the University of Crete, where he developed biosensor techniques to measure membrane molecule interactions for immune cells, and then undertook a postdoc at the Institut Curie to study how mechanical properties of T cell microenvironment affect their activation.
Dr Faruk Ramadani obtained his PhD in 2009 from the Babraham Institute, University of Cambridge, where he studied the role of class IA PI3K catalytic isoforms in lymphocyte development and function. He is currently a Research Fellow in the Randall Division of Cell and Molecular Biophysics at King’s College London, investigating the biology of human IgE-expressing cells. The aim of his research is to develop a new class of therapies for allergic disease and asthma.
Nicolas Poirier earned his PhD in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI). He joined the immune regulation company Effimune, where he led R&D programs for 7 years. He was appointed Chief Scientific Officer of OSE Immunotherapeutics in 2016, a biotechnology company in the field of immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and his R&D team is interested in identification and development of innovative immunotherapies.
Nguyen Tuan Huy conducts his research at the Inserm UMR1064 (Nantes, France). The limitations of organ transplantation drives his research in Sciences of Transplantations covering liver gene and cell therapy, keeping in mind that all of which face the barrier of the host immune system. He has a strong expertise in viral vectors including lentivirus, CRISPR-cas and pluripotent stem cells. His current research is focus on developing stem cell-based ATMPs to regenerate the patient’s liver.
Thomas Murarasu is passionate about science and innovation and is currently working at the Institut Curie on the development of a promising approach for cancer diagnosis and treatment. He graduated from AgroParisTech, French engineering school for food and life sciences, and obtained a Master of Science in systems and synthetic biology from Paris Descartes University. Based on his work as a PhD candidate, under the supervision of Ludger Johannes at Institut Curie, he is leading a start-up creation project to develop Lectibodies - innovative products used as alternatives to monoclonal antibodies for targeted delivery.
Dr Katy Lloyd has a strong background in immunity and inflammation, obtaining her PhD from the University of Liverpool. She is currently an industry-supported postdoctoral scientist at the Karolinska Institutet, Sweden. Her research focuses on understanding the role of autoantibodies and autoreactive B cells in the pathogenesis of rheumatoid arthritis, in addition to modifying monoclonal autoantibodies to generate potential therapeutics. Dr Lloyd has a keen interest in biotechnology and drug discovery.
Axel Hueber holds an MD and PhD in Immunology and is a research clinician and senior lecturer in the field of immunology and rheumatology. His focus is on cytokine biology in synovial inflammation and he also leads clinical trials, transferring knowledge from bench to bedside and vice versa and thus strongly supports basic research development.
Elie Hatem received his PhD in 2013 based on a thesis contemplating the mechanisms of cellular response to oxidative stress. He has been working for the last four years in revealing redox modulating capacities of commonly used drugs and their repurposing for cancer therapy. His objective is to launch a start-up company to allow for the emergence of new innovative therapies that will capitalize on redox modulating molecules to treat cancer and inflammatory diseases.
Marina Frleta Gilchrist
Dr Maria Frleta-Gilchrist is a clinical fellow in rheumatology at the Queen Elizabeth University Hospital and the Institute of Infection, Immunity and Inflammation at the University of Glasgow. Her passion for translational immunology developed through years of investigative work with leading rheumatologists - Professor Paul-Peter Tak at AMC Amsterdam and Professor Iain McInnes at the University of Glasgow -where she subsequently completed her PhD. Her work focuses on therapeutic and biomarker miRNA signatures in treatment resistant rheumatoid arthritis.
Elaine Del Nery was formally trained in biomedicine and obtained her PhD degree in the field of proteolytic enzymes. She was a visitor fellow at the University of Colorado Denver and joined the Curie Institut in Paris as a postdoctoral fellow to study intracellular protein trafficking. She has recently obtained additional university degrees in bioethics and patent research development. She currently holds a platform manager position, responsible for a variety of translational drug screening projects.
Maude Guillot-Delost obtained her PhD in Immunology in 2008. After a postdoc in the “Immunity and Cancer” unit (Institut Curie, Paris) and a postdoc in the team “Immuno-intervention and biotherapy” (CIMI, Paris), she is now a project manager at the Cancer Immunotherapy Center (Institut Curie, Paris). She now develops clinical programs aiming at prognostic/predictive biomarkers and targets identification in breast, head and neck and ovarian cancer.
Silvio Danese is a gastroenterologist and Head of the IBD Center at Humanitas Research Hospital and Professor in gastroenterology at Humanitas University in Milan, Italy.
His main research area of interest is the investigation of the fundamental mechanisms underlying IBD pathogenesis, while his daily clinical activity is related to IBD service. He is actively involved in many international clinical trials and has published more than 300 papers.
Jana Blaževski graduated as a molecular biologist and physiologist and defended her PhD in 2014 at the University of Belgrade, where she studied mechanisms of recovery of rats from experimental autoimmune encephalomyelitis. In 2015 she started her postdoc at the University of Oslo, characterizing a new mouse model to learn more about mechanisms of autoantibody formation in celiac disease. In October 2017 she will start on a new project aiming to develop cancer vaccines for patients with multiple myeloma.
Dr Peter Antal-Szalmas (MD, PhD) is a specialist in laboratory medicine, working as an associate professor at the Department of Laboratory Medicine, Debrecen University, Hungary. He defended his PhD at Utrecht University, in the Netherlands. He has a 15-year-long practice in diagnostics of oncological disorders and spent 10 years in the field of clinical immunology. He was the leader of 7 research grants providing around 1 million USD support. He has 57 publications with more than 1600 citations.
Wisam Alwan is a Dermatology Specialist Registrar (Resident) and Clinical Research Fellow at the St John’s Institute of Dermatology at King’s College London. He was recently awarded a Medical Research Council Clinical Research Training Fellowship to investigate the role of commensal bacteria in skin homeostasis and inflammatory skin diseases such as psoriasis and atopic dermatitis. Through this, Dr Alwan hopes to further our understanding of the pathogenesis of these diseases and potentially identify novel therapeutic targets.
Stefania Madonna received her degree in Chemistry from the University of Naples “Federico II” in 1999. In 2004, she completed her PhD in Biochemistry and Molecular Biology at the University of Naples “Federico II”. She is currently working as a researcher at the Laboratory of Experimental Immunology in the IDI-IRCCS Hospital in Rome, where she focuses on studying the inflammatory processes that occur in immune-mediated skin disorders. Dr Madonna has recently received Young Researcher funding from the Ministry of Health for her work in psoriasis.
Sonja Molin trained in Dermatology and Allergy at the Department of Dermatology and Allergy of the Ludwig Maximilian University in Munich, where she is currently working as an Assistant Professor. The main focus of her clinical expertise and research is the classification and pathogenesis of chronic hand eczema and psoriasis, occupational dermatology and contact allergies.
Sean Saunders is currently working as a postdoctoral research fellow at the Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland. He graduated in Biochemistry and obtained a PhD in Immunology. In 2014, he was chosen for an international scholarship to attend the 64th Lindau Nobel Laureate Meeting as one of “the next generation of leading scientists”. His research focuses on the molecular and cellular mechanisms that initiate allergic inflammation to elucidate targets for the treatment of immune mediated disease. His specific interest is in the skin, and the dynamic interaction between the skin barrier and immune homeostasis or dysregulation.
Rosa Andres Ejarque
Dr Rosa Andres Ejarque obtained her PhD in Biomedicine and Pharmacy from the University of Valencia in 2013 with the highest qualifications, as well as a Master's Degree in Research and Rational Use of Medicines. She then joined the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium, formed by world-leading dermatologists and industry partners, to develop clinical tests to help direct personalised treatments for psoriatic patients.
Dr Goldberg is a Clinical Research Fellow in Inflammatory Bowel Disease at Guy’s and St Thomas’s NHS Trust. She is also a PhD candidate at King’s College London working on the upcoming TRIBUTE trial of autologous regulatory T-cell therapy for Crohn’s Disease. Dr Goldberg is developing the product manufacture and immune monitoring protocols for the trial. Her interests are in developing novel and cell based therapies for Inflammatory Bowel Disease.
Naren Srinivasan is an immunologist with a strong background in biochemistry and biotechnology. His primary interests lie in inflammation biology and has experience in a wide array of fields including immunity, infections, cancer biology, and autoimmunity. Dr Srinivasan is particularly keen on translating primary research into novel therapeutic approaches. Apart from research, he has an avid interest in scientific writing and science journalism.
Margherita Coccia is a Bill and Melinda Gates Postdoctoral Fellow at GSK Vaccines. Her work uses system biology approaches to advance the development of vaccines for diseases of the developing world, in collaboration with Stanford University. She has a keen interest in translational research and public-private co-operation. She studied medical biotechnology and obtained a D.Phil. in Immunology from the University of Oxford.
Malin Winderdal earned her MD at the Karolinska Institute in 2004, followed by a research internship at Karolinska University Hospital in parallel to her postgraduate studies. In February 2015, Dr Winderdal earned her PhD from the Department of Medicine, the Karolinska Institute, which focused on the role of regulatory T-cells in urinary bladder cancer. Since then, she has continued as a Senior Scientist at Genagon Therapeutics AB and is undertaking part-time postdoctoral work in Immune Oncology.
Lisa van Baarsen
Lisa van Baarsen (PhD) is an Assistant Professor at the Amsterdam Rheumatology and Immunology Center in the Academic Medical Center. She has extensive experience in translational research focused on personalised medicine, biomarker discovery and lymph node immunobiology. Her research aims to unravel the biological processes leading to autoimmune diseases with an ultimate goal of discovering stage-specific drug targets and the development of tailor-made immunotherapies aimed at halting disease progression even before onset of disease.
Jorunn Stamnæs is a Master of Pharmacy from the University of Oslo and holds a PhD in Immunology from the Faculty of Medicine, University of Oslo. She currently works as a senior researcher at the University of Oslo, characterising the biology of the main B-cell autoantigen of the intestinal inflammatory disorder celiac disease. Dr Stamnæs’ research interests lies in the interphase between immunology, biochemistry and proteomics.
Helen Alexander is a Dermatology Trainee and currently is undertaking a National Institute for Health Research, Biomedical Research Centre-Francis Crick Institute, Clinical Training Fellowship at King’s College London. The focus of her research is the metagenomic analysis of the skin microbiome in healthy and inflamed skin. She aims for this work to become the basis of her PhD and ultimately contribute towards her long-term aim of becoming an Academic Dermatologist qualified in translational bioinformatics.
Guus Bol received his PhD in 2013 from the University of Utrecht, the Netherlands, in collaboration with the Johns Hopkins Medical Institute, US, where he developed a new drug for personalised cancer care. He is currently an oncologist in training at the University Medical Center Utrecht, the Netherlands, and the co-founder of two spin-off biotech companies. His main research interests are focused on developing novel therapeutics for clinical use by exploiting the underlying molecular mechanisms of tumor-immunology.
Grigory Ryzhakov obtained his PhD from the University of Cambridge and currently works as a molecular immunologist at the Kennedy Institute of Rheumatology, University of Oxford. He investigates novel molecular mechanisms regulating gut immunity and homeostasis. Dr Ryzhakov is particularly interested in how Th17 cells, and the molecules they produce, exert their pathogenic function in inflammatory bowel disease.
Gökçe Günaydin holds a BSc degree in Molecular Biology and Genetics from Bilkent University, Turkey (2008), and a PhD degree in Medical Science from Karolinska Institutet, Sweden (2014). She has previously been involved in the identification of genetic susceptibility markers in rotavirus infection and has developed a novel engineered antibody based immunotherapy. She has worked as a scientific consultant in a national start-up company, and been selected as a top-5 finalist in Sweden in the Global Impact Competition based in Silicon Valley (2015). Currently, she is working as a postdoctoral researcher on safety and efficiency of an anti-HIV microbicide, Griffithsin, in non-human primates, and testing drugs in human tissue explant models for HIV infection.
Dr McCann is the group leader in the Kennedy Institute of Rheumatology at the University of Oxford. She works at the clinical/basic science interface with pharma, steering strategic research for translational studies in inflammatory diseases. With a specific interest in the pathobiology of fibrotic diseases, Dr McCann’s group is working with the Structural Genomics Consortium to identify and validate novel therapeutic targets in patient cell derived assays for research advancement and drug discovery.
Ehsan Sharif-Paghaleh is an Assistant Professor at the Department of Immunology at Tehran University of Medical Sciences and a Visiting Lecturer at the Division of Imaging Sciences, St Thomas’ Hospital, King’s College London, where he completed his PhD and postdoc. His research interests are Immune Regulatory Cell Therapy and Medical Imaging.
Dominik Filipp is an immunologist at the Institute of Molecular Genetics in Prague, The Czech Republic, who trained at the INSERM/CNRS, Marseille, France, and the University of Toronto, Canada. His research group focuses on immune cell signaling, tolerance and autoimmunity. This curiosity driven research overlaps with an interest for channelling outcomes from the laboratory to translational immunology including understanding the mechanism of gastrointestinal autoimmunity, identification of its relevant molecular targets and viable therapeutic approaches.
Carole Guillonneau is an immunologist at the INSERM UMR 1064 in Nantes, France. She did a post-doctorate in the laboratory of Nobel Laureate Professor Doherty in Australia, then obtained a permanent position at the CNRS in 2009. She currently leads a group that focuses on the biology of CD8+ Tregs and investigates their clinical potential in transplantation and immune-related diseases. She has several patents and is interested in entrepreneurship.
Andres Laguna Fernandez
Dr Laguna Fernandez has a strong background in cardiovascular disease and inflammation. He has dedicated the last ten years to investigating multiple aspects of atherosclerosis and aortic valve stenosis in three institutions: Valencia Clinical Hospital, Harvard University and the Karolinska Institute. He is currently exploring therapeutic strategies capable of promoting inflammation resolution in order to reduce cardiovascular morbidity and mortality using a group of specialised pro-resolving mediators derived from polyunsaturated fatty acids.
Vuk Savkovic graduated in Biology at the Belgrade University and completed his PhD in Molecular Immunology at Leipzig University. As a principal investigator at the Translational Centre for Regenerative Medicine in Leipzig, his research focuses on the therapeutic potential of the outer root sheath of hair follicle (melanocytes, keratinocytes, MSCs, and endothelia).
Jan Leipe is a rheumatologist and works as an attending physician, supervising the Early Arthritis Clinic at the Division of Rheumatology and Clinical Immunology, University of Munich. Besides conducting clinical trials, his research activities are mainly focused on basic, translational, and clinical immunology with the aim of understanding the role of pro-inflammatory T-cell subsets (e.g. Th17 cells) in the pathogenesis of autoimmune diseases, particularly rheumatoid arthritis.
Victor Turcanu is a senior lecturer in allergy at King’s College London. He is a specialist physician in internal medicine and was awarded a PhD in Immunology and Immuno-pharmacology at the Louis Pasteur University, Strasbourg, France. Dr. Turcanu's main research interests concern immunomodulation and the immunomodulatory treatment of allergies.
Jana Burkhardt is currently the Junior Research Group Leader at the TRM and the Fraunhofer IZI Leipzig. Her project focuses on gene therapy for immune diseases. She studied biochemistry and obtained her PhD in genetics and immunology. She has been concurrently studying medicine since 2009 and is an MD candidate in the genetics of dyslexia. She has a keen interest in public scientific communication.
Hans Ulrich Scherer
Hans Ulrich Scherer is Internist-Rheumatologist at Leiden University Medical Center, The Netherlands. He received training in immunology at Tübingen University and in rheumatology at Charité University Hospital Berlin, Germany. He is a physician scientist with specific research interest in the pathophysiology of rheumatoid arthritis. His scientific work focuses on the biology of autoreactive B cells and on the glycobiology of autoantibodies.
Fergus McCarthy graduated from University College Cork in 2003 and currently works as an academic clinical lecturer at King’s College/St Thomas’ Hospital in London. Dr McCarthy received his PhD in 2012 and has a Masters in Epidemiology from the University of London. Dr McCarthy has over 50 publications, multiple awards and in 2014, received a scholarship to attend the 64th Lindau Nobel Laureate Meeting as one of “600 most qualified young researchers” chosen internationally.
Derek Gilchrist leads a tendinopathy drug discovery program at the University of Glasgow where, in close partnership with clinicians, he is developing and commercializing TenoMiR™, a novel miRNA replacement therapy for the treatment of human and equine tendinopathies. His enthusiasm and knowledge are dedicated to the discovery of novel translational therapies.
Carlo Selmi is the head of the Division of Rheumatology (Humanitas Research Hospital, Milan), Assistant Professor of Rheumatology (University of Milan), and Assistant Professor of Medicine (University of California, Davis). He is the co-author of 230 peer-reviewed publications and has an H index of 49. His research track includes autoimmunity and chronic inflammation.
Velizar Shivarov is currently head of the Immunology Lab at the second biggest private hospital in Bulgaria. He obtained an MD in 2003, a PhD in Immunology in 2011, and an MSc in Advanced Oncology in 2014. He was post-doc at Kyoto University and Yale University. The research focus of Dr. Shivarov is molecular biology of B cells and molecular diagnostics of myeloid malignancies.
Scott Werneke received his PhD in Immunology at the Washington University in St. Louis, United States and is currently a post-doctoral fellow at the Institut Pasteur, Paris, France. His research focuses on cytokine-mediated immune regulation as well as the development of single molecule assays for clinical biomarkers.
Kilian Eyerich is a senior physician at the Department of Dermatology and Allergy at the Technische Universität Munich, Germany. His clinical focus is inflammatory and autoimmune skin diseases. In 2014, he became the assistant professor for experimental dermato-immunology at the Technische Universität Munich. His scientific interest is on interaction of T lymphocytes and epithelial cells in inflammatory skin diseases.
Jeroen den Dunnen
Jeroen den Dunnen is an immunologist at the Academic Medical Center (AMC) in Amsterdam, The Netherlands. His group studies the induction of inflammation by Fc receptors during bacterial infections, rheumatoid arthritis, and inflammatory bowel disease, with the aim to identify new targets for therapy for these diseases.
Jagtar Singh Nijjar
Jagtar Singh Nijjar is an MRC Fellow in Rheumatology and interrogates the interface of rheumatology with Polyomics and data science. He also investigates the role of kinase inhibitors in pre-clinical studies and has active collaborations with academic and industrial partners in the area of biomarker discovery and stratified medicine.
Guttorm Haraldsen is the principal investigator of experimental pathology at the Oslo University Hospital. His project aims at generating inhibitory compounds that target selected aspects of the notch signalling pathway to treat inflammatory diseases. He trained at the University of Oslo (PhD) and Stanford University (postdoc). He currently heads a research group of 16 scientists and technical staff.
Dong Wang obtained his MD from China and PhD from Germany. He is a postdoctoral researcher in the University of Oslo/University Hospital/Norwegian National Hospital. His main projects focus on microenvironmental factors that allow genesis, maintenance, and expansion of lymphatic-originated neoplasms, e.g. chronic lymphocytic leukemia, angioimmunoblastic T-cell lymphoma, and multiple myeloma.
Denis Khnykin is a senior researcher at the Department of Pathology at National Hospital, Oslo, Norway. His PhD project was related to cancer research. Over the last five years, his research focus has been on the dynamic interaction between the skin and the immune system. He is particularly interested in elucidation of the role of keratinocytes in triggering chronic inflammatory skin diseases.
Conny van der Laken
Conny van der Laken is a rheumatologist and senior researcher and leads the research line “Advanced imaging of inflammatory rheumatic diseases (with focus on positron emission tomography [PET])”. Her work focuses on investigation of PET (CT/MRI) imaging with application of tracers targeting specific immunological targets for application of early diagnostics and therapy monitoring/prediction of inflammatory rheumatic diseases.
Claudia Mitrofan is a PhD student enrolled in the Wellcome Trust Metabolic Science and Cardiovascular Disease PhD program at the University of Cambridge, UK. Her research focuses on atherosclerosis and endothelial inflammation. She is interested in entrepreneurship, the drug development process, and commercialization of scientific ideas.
Ashley Miller is a Leadership Fellow at the Institute of Cardiovascular and Medical Sciences, University of Glasgow, where she studies the immune system in cardiovascular diseases. Prior to this, she held a BHF Intermediate Research Fellowship and carried out post-docs at the Karolinska Institute and Organon Laboratories.
Anita Kavlie is a senior researcher at the Oslo University Hospital. Her research aims at blocking the notch pathway to treat inflammatory diseases. She obtained her master’s degree from the University of Bergen and PhD from the University of Oslo. She is the co-inventor of four antibodies, patented and in clinical trials.
David Walcott is currently pursuing postgraduate studies in immunology at the University of Oxford. He qualified in 2010 from the UWI, Jamaica, and co-founded two small businesses during his medical internship. Under the tenure of the Jamaica Rhodes Scholarship, he furthered his studies at the University of Oxford with an MSc in Integrated Immunology, followed by his D Phil in Clinical Medicine/Immunology in which he is currently investigating signalling pathways in Crohn’s disease.
John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also a consultant immunologist within King's Health Partners and Barnet & Chase Farm NHS Trust.
Khondaker Rahman graduated as a pharmacist from the Faculty of Pharmacy of University of Dhaka, Bangladesh in 1996. He completed his PhD in Medicinal Chemistry at the London School of Pharmacy in 2009 and joined the CRUK Protein-Protein Interaction Research Group as a CRUK Research Fellow in July 2009. He was appointed Lecturer of Medicinal Chemistry at King’s College London in May 2012. He is a scientific co-founder of the university spin out biotech company Transcriptogen Limited.
Fabiola Atzeni received her degree in Medicine in 1995 from University of Cagliari and accreditation in Rheumatology in 2000. She received her Philosophy Doctorate in Experimental Immunology from University of Barcelona.
She is currently Senior Clinical Researcher and Consultant in Rheumatology (Qualified as Associate Professor in December 2013) at L.Sacco University Hospital of Milan, Italy.
Her clinical and research interest lies in immunotherapies in autoimmune diseases with particular focus on the investigation and management of differential response to biological therapies in rheumatoid arthritis and Spondyloarthritis, and cardiovascular aspects of the different rheumatic diseases with particular emphasis on arteriosclerosis.
Dirk Elewaut, MD, PhD is a Professor of Medicine and Chair of the Department of Rheumatology at Ghent University Hospital, a EULAR and FOCIS center of excellence. Over the past 20 years his work has focused on translational aspects of immune regulation to combat inflammatory arthritis and associated joint damage, with special focus on the link between gut and joint inflammation in spondyloarthritis.
Anthony Williams is an Associate Professor and Consultant in Clinical Immunology and Allergy at the University of Southampton/University Hospital Southampton NHS Trust. Following clinical training in London, Cardiff and Oxford, he undertook a Wellcome Trust Research Training PhD programme in Antigen Presentation at the Weatherall Institute of Molecular Medicine, Oxford. He has broad interests across translational immunology practice including immunodeficiency, allergy, cancer immunotherapeutics and quality assured laboratory practice. He is currently Director of the Southampton Centre for Biomedical Research Translational Research Laboratory and Co Director of the Southampton Experimental Cancer Medicine Centre.
Andrew Webb qualified from Charing Cross & Westminster Medical School in 1994, having intercalated a BSc in physiology. After General Professional Training in Brighton, he started his Specialist Registrar training in Clinical Pharmacology & General Medicine at Barts in 1998. He returned in 2003 to undertake his PhD [on nitrite-derived NO in the cardiovascular system] at Queen Mary University London and was appointed as Senior Lecturer/Honorary Consultant there in 2007. He moved to King’s College London in 2010 where he is Senior Lecturer/Honorary Consultant of Clinical Pharmacology.
Paolo Macor, PhD, is a biotechnologist researcher at the University of Trieste (Italy) and member of the PhD course in Nanotechnology. He performs translational research and is involved in the development of targeted-antibodies or targeted-nanoparticles for the treatment of haematological tumours or inflammatory processes.
Dirk Elewaut, MD, PhD is a Professor of Medicine and Chair of the Department of Rheumatology at Ghent University Hospital, a EULAR and FOCIS center of excellence. Over the past 20 years his work has focused on translational aspects of immune regulation to combat inflammatory arthritis and associated joint damage, with special focus on the link between gut and joint inflammation in spondyloarthritis.
Wan-Fai Ng is a Professor and Honorary Consultant in Rheumatology at Newcastle University. He leads the UK primary Sjögren’s syndrome registry. His research focuses on dissecting the relationships between biological disturbances and clinical manifestations of primary Sjögren’s syndrome, with the ultimate goal of developing more individualised treatment for this condition.
Vincent Mallet, MD, PhD is managing senior physician and Professor in the Department of Hepatology at Cochin University Hospital (Director Professor Stanislas Pol) and Research Director of Cellular Immunology in viral hepatitis at the French National Institute of Health (Inserm). Vincent Mallet works on basic and clinical aspects of hepatitis virus infections since 1999.
Sophia Karagiannis heads a cancer antibody discovery group specialising in dissecting B cell and antibody immune responses and in designing monoclonal antibodies and derivatives of different classes for the treatment of solid tumours. Her team is now preparing a first-in-man clinical study of an IgE class therapeutic candidate.
Seiamak Bahram, MD, PhD, is Professor of Medicine (Immunology), Dean of Research and Head, Department of Immunology, at the Strasbourg School of Medicine. He is senior member of Institut Universitaire de France, did post-doctoral research at Harvard Medical School and was scientific member of the Basel Institute for Immunology.
Geert D’Haens is Professor of Medicine at the Academic Medical Centre in Amsterdam, trained at the University of Chicago Hospitals and the University of Leuven. D’Haens is a global thought leader in inflammatory bowel diseases. He is currently deputy chairman of IOIBD and co-founder and honorary member of ECCO. Professor D’Haens is also Director of the European Office of the CRO Robarts Clinical Trials, based in Amsterdam. He has published over 200 peer-reviewed papers.
Elia Stupka’s career in genomics began working on the human genome in Cambridge, UK and subsequently in Singapore, Italy and London. He developed a translational genomics centre at San Raffaele Hospital serving a community of approximately 1,500 scientists. Since July 2014 he works as Head of Computational Biology at Boehringer Ingelheim in Germany.
Alexander Navarini is a clinical dermatologist specialized in neutrophil-mediated inflammatory conditions. His research aims to identify and validate therapeutic targets using next generation sequencing and experimental immunology. Recently, he identified genomic association signals in the TGF-β pathway in severe acne and missense mutations in the IL36RN gene in pustular conditions.
Zheng-liang Zhi is a research scientist at King’s College London, developing nanomedicine-based strategies for delivery of protein and cell therapies for diabetes treatment. His research also includes co-localised delivery of anti-inflammatory therapeutics for improving microenvironment of islet transplants. His recently developed technology and patents have led to a $50m private (VC & Angel) investment for synthetic vaccine development.
Stefan Nierkens is Head of the Utrecht center for Diagnostic Advances in Immunology Research, U-DAIR, UMCU, The Netherlands. His intramural laboratory facilitates translational research in clinically well-defined cohorts of patients suffering from inflammatory and immune-mediated diseases. He is also leading a research group on dendritic cell vaccination in SCT patients.
Sander Tas is an Internist-Rheumatologist at the Academic Medical Center (AMC)/University of Amsterdam, The Netherlands. His research interests include translational immunology with a focus on the molecular regulation of inflammation, in particular the role of NF-kappaB signaling and angiogenesis in immune-mediated inflammatory diseases using rheumatoid arthritis as a model disease. This involves both fundamental mechanistic studies, analysis of patient materials and targeted intervention in pre-clinical models.
Javier Martin is Professor of Human Genetics at Instituto de Parasitologia y Biomedicina, Spanish National Research Council (CSIC) belonging to the Spanish Ministry of Science and Innovation. His research is on the genetic of human autoimmune diseases with rheumatic component. He is the author of more than 400 scientific publications.
Jasper Broen received his PhD, based on a thesis contemplating the genetics of systemic sclerosis in 2012. He currently works as Assistant-Professor and rheumatologist in training in the Utrecht University Medical Center, Utrecht, Netherlands. His current main research interests are cellular senescence and bio-ageing processes in inflammatory diseases.